Citius Oncology, Inc. CTOR Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s increase (decrease) in accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s increase (decrease) in accounts receivable?
- Citius Oncology, Inc. (CTOR) reported increase (decrease) in accounts receivable of $4.05M in Q4 2025.